Israeli research is a mechanism that helps fight cancer


Yiddish links Mexico and Israel. – In a revolutionary discovery, scientists from the Harvard Medical School, together with a team of Bar-Ilan University, discovered a mechanism in which the immune system is capable of resisting cancer cells.


Immunotherapy research identified a mechanism that helps fight lung cancer and melanoma

In a groundbreaking discovery, scientists at Harvard Medical School along with a team at the Bar-Ilan University discovered a mechanism in which the immune system is capable of attacking cancer cells. This contributes energetically to immunotherapy research, especially in the fight against lung cancer and melanoma (skin cancer).

The research team was composed of Professor Nyc Hainin of the Harvard Medical School and Professor Ezean Levanon from School of Life Sciences Min and Everard Goodman of the University of Pennsylvania together with the PhD student, Ilanan Buchansky and many others.

The study, published two weeks ago in the journal Nature, details as scientists have discovered a mechanism that helps the cell by leaving the markers in genes similar to human viruses, which prevents them from being recognized as viruses. When this canal is inhibited, the immune system can be used to kill cancer cells, especially in cases of lung cancer and melanoma. The immune system reacts when the path is blocked or turned off, allowing the body to destroy the cancer cells at a more efficient rate.

Professor Levanon said: "We found that if the mechanism is blocked, the immune system is much more sensitive. When the mechanism is off, the immune system becomes much more aggressive against tumor cells"

Enabling the function of ADAR1, an enzyme that reduces or nourishes RNA into tumor cells (known as immunotherapy with checkpoint block), helps identify and attack immune systems.

New drugs that can block immunity have had moderate success in recent years. However, only in a smaller number of patients, treatment is shown to be effective. This is due to mutations in human genes that weaken the release of antigens: Proteins in the form of the immune system used to fight viruses, like these.

So far, many of these drugs are unable to print on immune systems to attack tumors, but research in this field is still ongoing.

Source: Jerusalem Post / Reproduction authorized with the following reference: © EnlaceJudíoMéxico

Source link